Health Secure A.I CyberSecurity Scoring
29/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Health Secure in 2026.
No incidents recorded for Health Secure in 2026.
No incidents recorded for Health Secure in 2026.
Pharmaceutical Manufacturing
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.
Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.
A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Latest updates, reports, and threat intel affecting the global network.
Why Now? The Rising Cyber Threats Driving HIPAA Reform- In December 2024, the U.S. Department of Health and Human Services Office for...
BOISE, Idaho — A Treasure Valley-based health center has reported that one of its third-party vendors has experienced a data breach,...
Jefferson-Blount-St. Clair Mental Health Authority in Alabama, Cottage Hospital in New Hampshire, WindRose Health Network in Indiana,...
Based on our market forecast, the healthcare security systems market to expand from USD 14.18 bn in 2025 to USD 35.27 bn by 2034,...
Healthcare systems are increasingly targeted by cyberattacks that can disrupt care delivery, expose sensitive patient information,...
Healthcare organizations stand at a critical juncture. Social engineering is more sophisticated, and threat actors are looking for bigger...
How Does Agentic AI Revolutionize Healthcare Security? Are you prepared to explore the transformative power of Agentic AI in securing the...
Healthcare Interactive, better known as HCIactive, reported a data breach to the HHS' Office for Civil Rights on September 22, 2025,...
The first step towards creating a robust cybersecurity program for medical devices is to identify medical devices with network capability and document all.
h2o is an HTTP server with support for HTTP/1.x, HTTP/2 and HTTP/3. Prior to commit 6b5370d, h2o is vulnerable to a Denial of Service attack when calling alloca under certain conditions. When serving static files, h2o builds the file path on stack, by calling alloca. The maximum size of the memory allocated using alloca can be as huge as ~600KB, which exceeds the default pthread stack size used by musl libc (128KB). If the amount of memory allocated by alloca exceeds the stack size, the h2o server crashes with a segmentation fault, while it tries to touch the guard page. This issue has been fixed by commit 6b5370d.
h2o is an HTTP server with support for HTTP/1.x, HTTP/2 and HTTP/3. Prior to commit 8dc37cb, when h2o receives a ClientHello message over TLS or QUIC and it contains a zero-length SNI extension, the h2o server runs over the zero-length hostname while trying to copy the hostname, assuming that it is NULL-terminated. This is a potential denial-of-service attack vector in sense that it might trigger segmentation violation. This issue has been fixed by commit 8dc37cb.
Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit 8b178e6, Quicly is vulnerable to a Denial of Service attack through connection state corruption. In QUIC Invariants, the maximum length of a Connection ID is 255 bytes, while QUIC version 1 further restricts the maximum to 20 bytes. Quicly implements QUIC version 1 and therefore its CID buffers are limited to 20 bytes. However, to be able to respond to unknown versions of QUIC, its packet decoder accepts Connection IDs of up to 255 bytes. As its CID buffers are merely 20 bytes long, Quicly must reject QUIC version 1 packets with Connection IDs longer than that. The command line tool bundled with Quicly has had that check, however the library itself lacked such enforcement. As a consequence, when used by applications that lack their own enforcement, the connection state becoming inconsistent to buffer overrun. Fortunately, the overflow stops within the allocated chunk of memory, but nevertheless, the bug leads to assertion failures. This issue has been fixed by commit 8b178e6.
Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit 937d0e9, an assertion failure is raised when the total number of valid handshake messages received over a CRYPTO stream of a single packet number space exceeds 32KB, causing a Denial of Service. This issue has been fixed by commit 937d0e9.
Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit dccf5d4, Quicly was vulnerable to stateless reset injection through lack of packet entry validation. The QUIC protocol is designed to withstand packet injection attacks, once the handshake is complete. Only packets that carry some secret patterns are considered as stateless resets. Quicly allows the peer to share up to 4 such patterns per connection. However, until now, it failed to determine which of the 4 slots that it uses to retain the secret patterns contains a valid entry. As the slots are zero-initialized, the failure meant that, unless the peer advertised 4 of such patterns, an all-zero pattern was treated as a stateless reset.In effect, this allowed an on-path attacker to reset QUIC connections governed by Quicly. This issue has been fixed by commit dccf5d4.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.